Madrigal Pharmaceuticals price target raised to $443 from $427 at Citizens JMP
Citizens JMP raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $443 from $427 and keeps an Outperform rating on the shares.
Madrigal CEO on Q4 earnings beat, MASH drug market opportunity
Bill Sibold, Madrigal Pharmaceuticals CEO , joins 'Fast Money' to talk quarterly results.
Why Madrigal Pharmaceuticals Stock Is Soaring Today
Shares of Madrigal Pharmaceuticals ( MDGL 16.35%) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...
Madrigal Pharmaceuticals price target raised to $469 from $378 at Citi
Citi raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $469 from $378 and keeps a Buy rating on the shares post the Q4 ...
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and ...
BioPharma Dive21h
AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch
The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...
Mets' Nick Madrigal dislocates non-throwing shoulder in spring game against Nationals
Nick Madrigal is fighting for a roster spot with the Mets, and it’s unclear how much time he’ll miss after the injury to his ...
Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...
Manaea is expected to miss start of Mets season with oblique strain. Madrigal has fractured shoulder
New York Mets starter Sean Manaea is expected to begin the season on the injured list because of a right oblique strain.
MLB2d
Madrigal 'out for long time' with fracture in left shoulder
The Mets’ bench competition experienced some early upheaval on Sunday, when infielder Nick Madrigal dislocated his left ...
We're Not Worried About Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn
But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So, the natural question for Madrigal Pharmaceuticals (NASDAQ:MDGL) shareholders is whether ...